Hypertension associated with reduced plasma thrombomodulin levels and a hypercoagulable state in rats

Clinical and Experimental Hypertension

Volumn 25, Issue 2, 2003, Pages 73-84

  Sawada, Kazuyoshi ^a,b   Naiki, Mitsuru ^a   Yago, Hisashi ^a   Matsushita, Kohji ^b   Ohtsuki, Toshiho ^b   Kitagawa, Kazuo ^b   Matsumoto, Masayasu ^b   Hori, Masatsugu ^b  

^a Nippon Zoki Pharmaceutical Co   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

D dimer; Hypercoagulable state; Hypertension; Spontaneously hypertensive rat; Thrombin antithrombin complex; Thrombomodulin

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CELL DAMAGE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HYPERCOAGULABILITY; HYPERTENSION; MALE; NONHUMAN; PROTEIN DETERMINATION; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEART; HYPERTENSION; MALE; ORGAN SIZE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; THROMBOMODULIN;

EID: 0037328745     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-120017928     Document Type: Article

References (44)

1. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78(4):2249-2252.
2. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257(2):859-864.
3. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76(6):2178-2181.
4. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65(5):618-623.
5. Kazama M. Clinical evaluation of hemostatic molecular markers. Acta Haematol Jpn 1988; 51(8):1387-1394.
6. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76(10):2024-2029.
7. Chobanian AV. 1989 Corcoran lecture: Adaptive and maladaptive responses of the arterial wall to hypertension. Hypertension 1990; 15(6 Pt 2):666-674.
8. Lee RM. Vascular changes at the prehypertensive phase in the mesenteric arteries from spontaneously hypertensive rats. Blood Vessels 1985; 22(3):105-126.
9. McCarron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM. Adhesion molecules on normotensive and hypertensive rat brain endothelial cells. Proc Soc Exp Biol Med 1994; 205(3):257-262.
10. Vanhoutte PM. Endothelium and control of vascular function. Hypertension 1989; 13(6 Pt 2):658-667.
11. Cacoub P, Karmochkine M, Dorent R, Nataf P, Piette JC, Godeau P, Gandjbakhch I, Boffa MC. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996; 101(2):160-164.
12. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T, Shimada K. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16(3):455-461.
13. Makris T. Thrombomodulin levels in patients with arterial hypertension. Am J Med 1997; 103(4):331-332.
14. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary hypertension were improved by continuous prostacyclin thrapy. Circulation 2000; 102(22):2720-2725.
15. Erdem Y, Usalan C, Haznedaroglu IC, Altun B, Arici M, Yasavul U, Turgan C, Caglar S. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12(11 Pt 1):1071-1076.
16. Hsu CD, Copel JA, Hong SF, Chan DW. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol 1995; 86(6):897-899.
17. Naruse M, Kawana M, Hifumi S, Naruse K, Yoshihara I, Oka T, Kato Y, Monzen C, Kurimoto F, Ohsumi K, Hosoda S, Demura H. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential hypertension and ischemic heart disease. J Cardiovasc Pharmacol 1991; 17(Suppl 7):471-474.
18. Trifiletti A, Barbera N, Pizzoleo MA, Leone G, Lucifora S, Soraci S, Scamardi R, Pedulla M, Frisina N. Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. J Cardio Surg 1995; 36(5):483-485.
19. Sawada K, Yamamoto H, Yago H, Suehiro S. Changes in coagulation and fibrinolytic systems of SART-stressed (repeated cold stress) animal. International J Hematol 1994; 59(Suppl 1):310 (Abstract).
20. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries and lymphtics, and on syncytiotrophoblast of human placenta: J Cell Biol 1985; 101(2):363-371.
21. Ogura M, Ito T, Maruyama I, Saito H. Localization and biosynthesis of functional thrombomodulin in human megakaryocytes and a human megakaryoblastic cell line (MEG-01). Thromb Haemost 1990; 64(2):297-301.
22. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem (Tokyo) 1988; 104(4):628-632.
23. Pruna A, Peyri N, Berard M, Boffa MC. Thrombomodulin is synthesized by human mesangial cells. Kidney Int 1997; 51(3):687-693.
24. Harlan JM, Harker LA, Reidy MA, Gajdusek CM, Schwartz SM, Striker GE. Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest 1983; 48(3):269-274.
25. Sawada K, Yamamoto H, Yago H, Suehiro S. A simple assay to detect endothelial cell injury; measurement of released thrombomodulin from cells. Exp Mol Pathol 1992; 57(2):116-123.
26. Smedly LA, Tonnesen MG, Sandhaus RS, Haslett C, Guthrie LA, Johnston RB Jr, Henson PM, Worthen GS. Neutrophil-mediated injury to endothelial cells: Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 1986; 77(4):1233-1243.
27. Kanazuka M, Shigekiyo T, Toibana N, Saito S. Increase in plasma thrombomodulin level in patients with vibration syndrome. Thromb Res 1996; 82(1):51-56.
28. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001; 298(3):879-885.
29. Ohtsuki T, Matsumoto M, Suzuki K, Taniguchi N, Kamada T. Mitochondrial lipid peroxidation and superoxide dismutase in rat hypertensive target organs. Am J Physiol 1995; 268(4 Pt 2):H1418-H1421.
30. Tse WY, Maxwell SRJ, Thomason H, Blann A, Thorpe GHG, Waite M, Holder R. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens 1994; 8(11):843-849.
31. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8(12):5588-5592.
32. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73(1):159-165.
33. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83(10):3460-3464.
34. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151(5):1628-1631.
35. Liu Y, Liu T, McCarron RM, Spatz M, Feuerstein G, Hallenbeck JM, Siren AL. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 1996; 270(6 Pt 2):H2125-H2131.
36. Siren AL, Heldman E, Doron D, Lysko PG, Yue TL, Liu Y, Feuerstein G, Hallenbeck JM. Release of proinflammatory and prothrombotic mediators in the brain and peripheral circulation in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Stroke 1992; 23(11):1643-1651.
37. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256(1 Pt 2):H126-H131.
38. Greene AS, Tonellato PJ, Zhang Z, Lombard JH, Cowley AW Jr. Effect of microvascular rarefaction on tissue oxygen delivery in hypertension. Am J Physiol 1992; 262(5 Pt 2):H1486-H1493.
39. Dufourcq P, Seigneur M, Pruvost A, Dumain P, Belloc F, Amiral J, Boisseau MR. Membrane thrombomodulin levels are decreased during hypoxia and restored by cAMP and IBMX. Thromb Res 1994; 77(3):305-310.
40. Ogawa S, Shreeniwas R, Brett J, Clauss M, Furie M, Stern DM. Effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulation function. Br J Haematol 1990; 75(4):517-524.
41. Maruyama I, Majerus PW. The turnover of thrombin-thrombomodulin complex in culture human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin. J Biol Chem 1985; 260(29):15432-15438.
42. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75(4):895-901.
43. Key NS, Vercellotti GM, Winkelmann JC, Moldow CF, Goodman JL, Esmon NL, Esmon CT, Jacob HS. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci USA 1990; 87(18):7095-7099.
44. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110(3):710-717.